While evolocumab 420 mg monthly may represent a cost‐effective PCSK9 inhibitor option for Chinese hypercholesterolemia patients, further rigorous cost‐effectiveness analyses are warranted as well [42]. Here, PCSK9 is linked to familial hypercholesterolemia.